Source comparison
Hexarelin Safe Long Term Use: Growth Hormone Peptides Comparison
How does hexarelin compare to other GHSR agonists and GH secretagogues when extended protocols are considered? The table below contrasts receptor mechanisms, desensitization timelines, and documented long-term use constraints. Hexarelin GHSR-1a agonist (high a
This comparison does not assign a generated winner or score.
- How does hexarelin compare to other GHSR agonists and GH secretagogues when extended protocols are considered? The table below contrasts receptor mechanisms, desensitization timelines, and documented long-term use constraints.
- Hexarelin
- GHSR-1a agonist (high affinity)
- 12–16 weeks continuous use
- LV hypertrophy in canine models at 200mcg/kg; human data limited beyond 24 weeks
- 4–8 week cycles recommended; continuous use >16 weeks shows 40–60% GH response decline
- Potent but tolerance-prone; best suited for pulsed protocols with washout
- Ipamorelin
- GHSR-1a agonist (selective)
- Minimal documented desensitization up to 12 weeks
- No cardiac signals in animal or human studies
- Human trials extend to 12 weeks; anecdotal use reports up to 24 weeks without tolerance
- More sustainable for extended use; lower peak GH but stable response
- MK-677 (Ibutamoren)
- GHSR-1a agonist (orally active)
- Moderate tachyphylaxis by week 8–12; GH response declines 20–30% from baseline
- Increased appetite and transient insulin resistance; no structural cardiac changes
- Phase III trials ran 12–24 months; GH elevation persists but attenuates
- Oral convenience but appetite side effects limit compliance; better studied long-term than hexarelin
- CJC-1295 + Ipamorelin
- GHRH analog + GHSR-1a agonist (synergistic)
- CJC component stable; ipamorelin component shows minimal fade
- No documented cardiac concerns in combination protocols
- Combination protocols run 12–16 weeks in clinical settings
- Synergy reduces per-peptide dose requirements; likely more sustainable than hexarelin monotherapy
- GHRP-2
- GHSR-1a agonist (moderate selectivity)
- Moderate desensitization by week 10–14
- Cortisol/prolactin co-secretion higher than ipamorelin
- Research use documented to 16 weeks; cycling recommended
- Similar desensitization profile to hexarelin but lower peak GH; less studied
- GHRP-6
- GHSR-1a agonist (appetite stimulation)
- Similar to GHRP-2
- Strong appetite stimulation complicates metabolic research
- Typically used 4–8 weeks due to appetite effects
- Appetite side effect limits utility in body composition research; short-burst use only